Status:
COMPLETED
Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Staphylococcus Aureus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
S. aureus bloodstream infection (SAB) is a severe disease associated with a 30% case-fatality rate at 12 weeks. Severity of this disease is related to the high prevalence of staphylococcal Deep Foci o...
Detailed Description
Subjects will be recruited in medical wards of the 10 participating hospitals. Each included patient will be managed according to clinical expertise of investigators who all are experts in the field o...
Eligibility Criteria
Inclusion
- \- Aged over 18 years
- Signed informed consent form
- Subjects must be able to attend all scheduled visits and to comply with all trial procedures
- Subjects must be covered by public health insurance
- Hospitalized in one of the 10 participating centres
- At least one peripheral blood culture isolating S. aureus
- Absence of diagnosis of IE according to at least a transthoracic cardiac echography; cardiac echography will be performed via transesophageal procedure if the VIRSTA score is 3 or higher (see Appendix) or if transthoracic echography is not normal.
Exclusion
- \- Any reason that may compromise compliance with the visit plan
- Planned longer stay outside the region that prevents compliance with the visit plan
- Deprived of liberty subjects (by judicial or administrative decision)
- Adult under guardianshipCatheter-related SAB with resolution of symptoms of infection within 24 hours of ablation of catheter
- Pregnancy or lactation
- Isolation of S. aureus only in blood cultures drawn from a catheter or another implanted device
- Catheter-related SAB with resolution of symptoms of infection within 24 hours of ablation of catheter
- Uncontrolled septic shock and other instability contra-indicating the performance of PET/CT
- Previous performance of PET/CT for the present episode of SAB
- Indication to PET/CT for another reason (eg. neoplasm, infection of vascular graft…)
- Contra-indication to PET/CT
- Contraindication to Fluorodeoxyglucose : hypersensitivity to the active substance or to any of the excipients
- Participation to another study unless specific authorization of the steering committee
Key Trial Info
Start Date :
January 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 20 2025
Estimated Enrollment :
291 Patients enrolled
Trial Details
Trial ID
NCT03419221
Start Date
January 29 2018
End Date
March 20 2025
Last Update
April 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Gui de Chauliac
Montpellier, France, 34295